Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

NCT02113397 · clinicaltrials.gov ↗

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Insufficient enrollment

Conditions

Cystic Fibrosis

Interventions

DRUG: TOBI™ Podhaler™ 112 mg inhaled twice daily
DRUG: Colistimethate 75 mg inhaled two times daily

Sponsor

Dartmouth-Hitchcock Medical Center

Collaborators

[object Object]